CClinicalTrials.gg
Status unknownNCT03437642PSYCHONICUpdated Sep 18, 2019

Psyhosomatic Medicine in Oncologic and Cardiac Disease Study

An observational study in Acute Myocardial Infarction, Tako Tsubo Cardiomyopathy and Breast Cancer, sponsored by San Filippo Neri General Hospital. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by San Filippo Neri General Hospital · Observational

The sponsor has not verified this record recently (last verified Sep 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
220
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Psychological processes play a complex role in the pathophysiology of many diseases. However, the body and emotional perception of patients and the relationship between dreams and disease still need to be investigated.

The investigators planned an observational and controlled research aimed at assessing some previously unaddressed baseline psychological characteristics and their changes at 1 and 5 years after a short-term psychotherapy in carefully characterised patients with heart or oncologic diseases .

The patients that will be enrolled are:

  • 50 patients ≤ 75 year old with acute myocardial infarction;
  • 30 patients ≤ 75 year old with Tako-Tsubo syndrome;
  • 50 women ≤ 75 year old, recently operated on breast cancer:
  • 90 control subjects of the same age and gender of the enrolled patients, without relevant pathologies during the last 10 years. Relevant pathologies are defined as those that required a hospitalisation or a long-lasting medical therapy.

At the enrolment all the subjects will undergo a complete medical evaluation, and the following psychometric tests: Self-evaluation test, Social Support Questionnaire, Beck Depression Inventory II (BDI II), MacNew Heart Disease Health-Related Quality of Life Questionnaire, State-Trait Anxiety Inventory (STAI), State-Trait Anger Expression Inventory (STAXI 2).

In two distinct following meetings, an open questionnaire exploring the body and emotional perception, and another exploring past and recent dreams, will be administered.

The same evaluation will be done for the healthy subjects.

After the initial evaluation, all the patients will be given the choice to start a short-term psychotherapy lasting 6 months on top of medical therapy or to continue classic medical therapy only. Healthy subjects will be not offered the possibility to follow psychotherapy.

At first year of follow-up, the battery of psychometric test, and the two questionnaires exploring the body and emotional perception, and changes and characteristics of dreams during the psychotherapy, will be re-administered.

The following data will be evaluated:

Psychological characteristics at follow-up. Incidence of new relevant medical events Quality of life Relationship between psychological characteristics and health status, and quality of life

At 5 year follow-up psychometric tests and the clinical data will be evaluated in all the groups.

02

Conditions studied

  • Acute Myocardial Infarction
  • Tako Tsubo Cardiomyopathy
  • Breast Cancer
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  • 50 patients ≤ 75 year old with acute myocardial infarction;
  • 30 patients ≤ 75 year old with Tako-Tsubo syndrome;
  • 50 women ≤ 75 year old, recently operated on breast cancer:
  • 90 control subjects of the same age and gender of the enrolled patients, without relevant pathologies during the last 10 years. Relevant pathologies are defined as those that required a hospitalisation or a long-lasting medical therapy.

Inclusion criteria

  • Patients within one week from an Acute myocardial infarction treated with primary or urgent PCI
  • Patients within one week from the onset of Tako Tsubo cardiomyopathy.
  • Patients with a diagnosis of breast cancer in the preceding six months
  • Age and sex matched control subjects without relevant medical pathologies in the preceding 10 years

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment
  • Refusing the enrolment
04

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
220 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Tako-Tsubo - STP

    Short term psychotherapy + Classic cardiological therapy

    Behavioral: Short Term Psychotherapy

  • Tako-Tsubo - Control

    Classic cardiological therapy only

  • Oncologic - STP

    Short term psychotherapy + Classic oncological therapy

    Behavioral: Short Term Psychotherapy

  • Oncologic - Control

    Classic oncological therapy only

  • AMI - STP

    Short term psychotherapy + Classic cardiological therapy

    Behavioral: Short Term Psychotherapy

  • AMI - Control

    Classic cardiological therapy only

  • Healthy Subjects

    No therapy

Interventions

  • BehavioralShort Term Psychotherapy

    Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs

05

What researchers measure

Primary outcomes

  1. Cumulative incidence of new relevant medical events

    Relevant medical events are defined as any new medical condition significantly impairing normal daily activities or requiring hospitalization or needing specific and permanent drug treatment.

    Time frame: at 1 year

Secondary outcomes

  1. Cumulative incidence of new relevant medical events

    Relevant medical events are defined as any new medical condition significantly impairing normal daily activities or requiring hospitalization or needing specific and permanent drug treatment.

    Time frame: at 5 years

  2. Changes in body perception and dreams

    These changes will be evaluated with dedicated qualitative questionnaires formulated with open questions.

    Time frame: at 1 year

  3. Incidence of rehospitalisations

    Number of rehospitalisations during the first year of follow-up

    Time frame: at 1 year

  4. Incidence of rehospitalisations

    Number of rehospitalisations during 5 years follow-up

    Time frame: at 5 years

  5. Distress grade

    Self-evaluation test (score range 1-10, higher stress for higher values)

    Time frame: at 1 year

  6. Distress grade

    Self-evaluation test (score range 1-10, higher stress for higher values)

    Time frame: at 5 years

  7. Depression symptoms

    Beck depression inventory II (score range 0-63, more severe depression symptoms for higher values)

    Time frame: at 1 year

  8. Depression symptoms

    Beck depression inventory II (score range 0-63, more severe depression symptoms for higher values)

    Time frame: at 5 years

  9. Social support

    Social support questionnaire (score range 12-72, the higher the score the lower the support)

    Time frame: at 1 year

  10. Social support

    Social support questionnaire (score range 12-72, the higher the score the lower the support)

    Time frame: at 5 year

  11. Quality of life

    Mac New Health-related quality of life questionnaire (score range 1-7, the higher the score the higher the quality of life, 4 subscales not merged)

    Time frame: at 1 year

  12. Quality of life

    Mac New Health-related quality of life questionnaire (score range 1-7, the higher the score the higher the quality of life, 4 subscales not merged)

    Time frame: at 5 years

  13. Anxiety grade

    State-Trait Anxiety inventory (score range 20-80, the higher the score the more anxiety the patients has, 2 subscales)

    Time frame: At 1 year

  14. Anxiety grade

    State-Trait Anxiety inventory (score range 20-80, the higher the score the more anxiety the patients has, 2 subscales)

    Time frame: At 5 years

  15. Anger level

    State-Trait Anger Expression inventory (score range 0%-100%, the higher the score the higher the anger, two subscales)

    Time frame: at 1 year

  16. Anger level

    State-Trait Anger Expression inventory (score range 0%-100%, the higher the score the higher the anger, two subscales)

    Time frame: at 5 years

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Roncella A, Pristipino C, Di Carlo O, Ansuini M, Corbosiero A, Di Fusco SA, Palumbo G, Gigantesco A, Mirabella F, De Angelis R, Pasceri V, Cancellara L, Colivicchi F, Allan R, Mirri MA, Speciale G. PSYChosomatic Medicine in ONcologIc and Cardiac Disease (PSYCHONIC) Study-A Retrospective and Prospective Observational Research Protocol. J Clin Med. 2021 Dec 10;10(24):5786. doi: 10.3390/jcm10245786. PubMed 34945081 ↗
08

Registry details

Key details

Study ID
NCT03437642
Lead sponsor
San Filippo Neri General Hospital
Responsible party
Christian Pristipino (MD, Head of Research and Training section, Interventional Cardiology Unit, San Filippo Neri General Hospital) — Principal investigator
First posted
Feb 19, 2018
Start date
Mar 27, 2018
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Sep 18, 2019

Study contacts

Adriana Roncella, MD
Contact
adrianaroncella@hotmail.it
+39060633062504
Adriana Roncella, MD
principal investigator · San Filippo Neri General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion